The Role of Pneumococcal Pneumonia among Community Acquired Pneumonia in Adult Turkish Population: TurkCAP Study

OBJECTIVE: To evaluate the rate of pneumococcal pneumonia (PP) among patients with community-acquired pneumonia (CAP) in Turkey and to investigate and compare features of PP and non-PP CAP patients.MATERIAL AND METHODS: This multicenter, non-interventional, prospective, observational study included adult CAP patients (age ≥ 18 years). Diagnosis of PP was based on the presence of at least 1 positive laboratory test result for Streptococcus pneumoniae (blood culture or sputum culture or urinary antigen test [UAT]) in patients with radiographic findings of pneumonia.RESULTS: Four hundred sixty-five patients were diagnosed with CAP, of whom 59 (12.7%) had PP. The most common comorbidity was chronic obstructive pulmonary disease (30.1%). The mean age, smoking history, presence of chronic neurological disease, and CURB-65 score were significantly higher in PP patients, when compared to non-PP patients. In PP patients, 84.8% were diagnosed based ony on the UAT. The overall rate of PP patients among CAP was calculated as 22.8% considering the UAT sensitivity ratio of 63% (95% confidence interval: 45-81). The rate of intensive care treatment was higher in PP patients (P = .007). While no PP patients were vaccinated for pneumococcus, 3.8% of the non-PP patients were vaccinated (P = .235). Antibiotic use in the preceding 48 hours was higher in the non-PP group than in the PP group (31.8% vs. 11.1%, P = .002). The CURB-65 score and the rate of patients requiring inpatient treatment according to this score were higher in the PP group.CONCLUSION: The facts that PP patients were older and required intensive care treatment more frequently as compared to non-PP patients underline the burden of PP.

Tam Metin

Kaynakça

1. Henriques-Normark B, Tuomanen EI. The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med. 2013;3:a010215-a010215. [CrossRef]

2. Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: Burden of disease. Clin Microbiol Infect. 2014;20:45-51. [CrossRef]

3. Almirall J, Bolíbar I, Vidal J et al. Epidemiology of communityacquired pneumonia in adults: a population-based study. Eur Respir J. 2000;15:757-763. [CrossRef]

4. Kolditz M, Tesch F, Mocke L et al. Burden and risk factors of ambulatory or hospitalized CAP: a population based cohort study. Respir Med. 2016;121:32-38. [CrossRef]

5. Blasi F, Akova M, Bonanni P et al. Community-acquired pneumonia in adults: highlighting missed opportunities for vaccination. Eur J Intern Med. 2017;37(8118):13-18. [CrossRef]

6. Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017;358:j2471. [CrossRef]

7. Steel HC, Cockeran R, Anderson R, Feldman C. Overview of community-acquired pneumonia and the role of inflammatory mechanisms in the immunopathogenesis of severe pneumococcal disease. Mediators Inflamm. 2013;2013:490346. [CrossRef]

8. Holter JC, Müller F, Bjørang O et al. Etiology of communityacquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in norway. BMC Infect Dis. 2015;15(11):64. [CrossRef]

9. Ieven M, Coenen S, Loens K et al. Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 european countries. Clin Microbiol Infect. 2018;24:1158- 1163. [CrossRef]

10. Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-382. [CrossRef]

11. Saukkoriipi A, Pascal T, Palmu AA. Evaluation of the BinaxNOW® Streptococcus pneumoniae antigen test on fresh, frozen and concentrated urine samples in elderly patients with and without community-acquired pneumonia. J Microbiol Methods. 2016;121(5):24-26. [CrossRef]

12. Jain S, Self WH, Wunderink RG et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373:415-427. [CrossRef]

13. Broulette J, Yu H, Pyenson B, Iwasaki K, Sato R. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits. 2013;6:494-503. [CrossRef]

14. Bertsias A, Tsiligianni IG, Duijker G et al. Studying the burden of community-acquired pneumonia in adults aged ≥50 years in primary health care: an observational study in rural Crete, Greece. NPJ Prim Care Respir Med. 2014;24(11):14017. [CrossRef]

15. Kabundji DM, Musekiwa A, Mukansi M, Feldman C. Determining need for hospitalisation: evaluation of the utility of the CRB-65 score in patients with community-acquired pneumonia presenting to an emergency department. S Afr Med J. 2014;104:769-772. [CrossRef]

16. Kaysin A, Viera AJ. Community-acquired pneumonia in adults: diagnosis and management. Am Fam Phys. 2016;94:698-706. [CrossRef]

17. Parrott G, Nebeya D, Kinjo T et al. Etiological analysis and epidemiological comparison among adult CAP and NHCAP patients in Okinawa, Japan. J Infect Chemother. 2017;23:452- 458. [CrossRef]

18. Köksal I, Ozlü T, Bayraktar O et al. Etiological agents of community-acquired pneumonia in adult patients in turkey; a multicentric, cross-sectional study. Tuberk Toraks. 2010;58:119-127.

19. Spoorenberg SM, Bos WJ, Heijligenberg R et al. Microbial aetiology, outcomes, and costs of hospitalisation for communityacquired pneumonia; an observational analysis. BMC Infect Dis. 2014;14:335. [CrossRef]

20. Remington LT, Sligl WI. Community-acquired pneumonia. Curr Opin Pulm Med. 2014;20:215-224. [CrossRef]

21. Sahuquillo-Arce JM, Menéndez R, Méndez R et al. Age-related risk factors for bacterial aetiology in community-acquired pneumonia. Respirology. 2016;21:1472-1479. [CrossRef]

22. Harat R, Alexander R, Gray S et al. Prospective, populationbased surveillance of the burden of streptococcus pneumoniae in community-acquired pneumonia in older adults, chrzanów county, poland, 2010-2012. Pneumonol Alergol Pol. 2016;84:95-103. [CrossRef]

23. Cilloniz C, Ewig S, Gabarrus A et al. Seasonality of pathogens causing community-acquired pneumonia. Respirology. 2017;22:778-785. [CrossRef]

24. Naderi H, Sheybani F, Sarvghad M, Meshkat Z, Jabbari Nooghabi M. Etiological diagnosis of community-acquired pneumonia in adult patients: a prospective hospital-based study in Mashhad, Iran. Jundishapur J Microbiol. 2015;8:e22780. [CrossRef]

25. Gelfer G, Leggett J, Myers J, Wang L, Gilbert DN. The clinical impact of the detection of potential etiologic pathogens of community-acquired pneumonia. Diagn Microbiol Infect Dis. 2015;83:400-406. [CrossRef]

26. Camou F, Issa N, Bessede É, Mourissoux G, Guisset O. Usefulness of pneumococcal antigen urinary testing in the intensive care unit? Med Mal Infect. 2015;45:318-323. [CrossRef]

27. Choi MJ, Song JY, Cheong HJ et al. Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes. J Infect Chemother. 2015;21:672-679. [CrossRef]

28. Alici DE, Sayiner A, Unal S. Barriers to adult immunization and solutions: personalized approaches. Hum Vaccin Immunother. 2017;13:213-215. [CrossRef]

29. Demirdogen Cetinoglu E, Uzaslan E, Sayıner A et al. Pneumococcal and influenza vaccination status of hospitalized adults with community acquired pneumonia and the effects of vaccination on clinical presentation. Hum Vaccin Immunother. 2017;13:2072-2077. [CrossRef]

30. van Werkhoven CH, Bonten MJ. The community-acquired pneumonia immunization trial in adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly? Future Microbiol. 2015;10:1405-1413. [CrossRef]

31. Ullah S, Khan J, Khan A, Hashemy I. Assessing decision of inpatient or outpatient care in community acquired pneumonia: APT care study. J Pak Med Assoc. 2017;67:380-385.

32. Guo Q, Li HY, Zhou YP et al. Compliance with the CURB-65 score and the consequences of non-implementation. Int J Tuberc Lung Dis. 2011;15:1697-1702. [CrossRef]